Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:502631.
doi: 10.1155/2011/502631. Epub 2011 Dec 7.

Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension

Dexter L Lee  1 , Justin L Wilson, Rong Duan, Tamaro Hudson, Ahmed El-Marakby
Affiliations

Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension

Dexter L Lee et al. PPAR Res. 2011.

Abstract

Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenofibrate reduces blood pressure and sodium retention during DOCA-salt hypertension. PPAR-α activation reduces the expression of inflammatory cytokines, such as interleukin-6 (IL-6). Fenofibrate also induces cytochrome P450 4A (CYP4A) and increases 20-hydroxyeicosatetraenoic acid (20-HETE) production. This study tested whether the administration of fenofibrate would reduce blood pressure by attenuating plasma IL-6 and renal expression of cyclooxygenase-2 (COX-2), while increasing expression of renal CYP4A during 7 days of DOCA-salt hypertension. We performed uni-nephrectomy on 12-14 week old male Swiss Webster mice and implanted biotelemetry devices in control, DOCA-salt (1.5 mg/g) treated mice with or without fenofibrate (500 mg/kg/day in corn oil, intragastrically). Fenofibrate significantly decreased mean arterial pressure and plasma IL-6. In kidney homogenates, fenofibrate increased CYP4A and decreased COX-2 expression. There were no differences in renal cytochrome P450, family 2, subfamily c, polypeptide 23 (CYP2C23) and soluble expoxide hydrolase (sEH) expression between the groups. Our results suggest that the blood pressure lowering effect of PPAR-α activation by fenofibrate involves the reduction of plasma IL-6 and COX-2, while increasing CYP4A expression during DOCA-salt hypertension. Our results may also suggest that PPAR-α activation protects the kidney against renal injury via decreased COX-2 expression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean arterial pressure during a seven-day treatment period in control mice, DOCA-salt-treated (1.5 mg/g) group and a DOCA + fenofibrate-treated (500 mg/kg/day) group. C: control days, D: DOCA salt days (*P < 0.05).
Figure 2
Figure 2
Kidney- and heart-weight-to-body-weight ratios in control, DOCA-salt-treated, and DOCA + fenofibrate-treated mice.
Figure 3
Figure 3
Plasma interleukin-6 on day seven of DOCA-salt hypertension in control, DOCA and DOCA + fenofibrate-treated mice (*indicates DOCA significantly increased plasma IL-6 when compared to control and DOCA + fenofibrate; P < 0.05).
Figure 4
Figure 4
Western blot expression and analysis of (a) COX-2, (b) CYP4A, (c) CYP2C23, and (d) sEH in whole-kidney homogenates taken from control, DOCA, and DOCA + fenofibrate mice (*indicates DOCA + fenofibrate significantly reduced COX-2 expression when compared to DOCA alone. ≠indicates DOCA + fenofibrate COX-2 expression was significantly higher than the control group. *indicates DOCA and DOCA + fenofibrate have significantly different renal CYP4A expression when compared to control. ≠indicates DOCA + fenofibrate renal expression of CYP4A is significantly increased when compared to DOCA (P < 0.050)).
Figure 5
Figure 5
Urinary albumin excretion on day seven in control, DOCA, and DOCA + fenofibrate-treated mice. *indicates DOCA albumin excretion is significantly different from control and DOCA + fenofibrate-treated mice.
See this image and copyright information in PMC

References

    1. Obih P, Oyekan A. Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice. Blood Pressure. 2008;17(1):55–63. - PubMed
    1. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension. 1993;21(6):985–988. - PubMed
    1. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005;45(4):730–735. - PubMed
    1. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-α activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005;46(2):366–371. - PubMed
    1. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31(1):225–231. - PubMed